Results 1 to 10 of about 3,067,072 (318)

JAK Inhibitors in Psoriatic Disease

Clinical, Cosmetic and Investigational Dermatology, 2023
Matteo Megna,1 Luca Potestio,1 Angelo Ruggiero,1 Sara Cacciapuoti,1 Francesco Maione,2 Marco Tasso,3 Francesco Caso,3,* Luisa Costa3,* 1Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples,
Megna M, Potestio L, Ruggiero A, Cacciapuoti S, Maione F, Tasso M, Caso F, Costa L   +7 more
doaj   +9 more sources

JAK inhibitors in rheumatology

Immunological Medicine, 2023
Janus kinase inhibitors (JAKis) are a group of drugs with a different mechanism of action from biologics and are most rapidly uptaken in the rheumatology field.
Kunihiro Yamaoka, Kenji Oku
doaj   +5 more sources

JAK inhibitors ∼ overview∼

Immunological Medicine, 2023
Among various tyrosine kinases, a family of Janus kinases (JAK) has been elucidated as key players in signal transduction from vital cytokine receptors, such as interleukins and interferons.
Hideto Kameda
doaj   +5 more sources

Infectious retinitis associated with JAK inhibitors: the ongoing duality of JAK inhibitors [PDF]

International Journal of Retina and Vitreous
Purpose To discuss the recent evidence that Janus kinase (JAK) inhibitors can cause viral retinitis. Methods A commentary on the case report in this issue and a review of cases in the literature.
Jose S. Pulido, Fukutaro Mano, Marcello Casella, Susumu Ishida   +3 more
doaj   +4 more sources

JAK inhibitors and COVID-19

Journal for ImmunoTherapy of Cancer, 2022
During SARS-CoV-2 infection, the innate immune response can be inhibited or delayed, and the subsequent persistent viral replication can induce emergency signals that may culminate in a cytokine storm contributing to the severe evolution of COVID-19. Cytokines are key regulators of the immune response and virus clearance, and, as such, are linked to ...
Gabriel Levy, Paola Guglielmelli, Peter Langmuir, Stefan Constantinescu   +3 more
doaj   +7 more sources

The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies

Frontiers in Pharmacology, 2022
Background: Due to the lack of comprehensive evidence based on prospective studies, the efficacy and safety of Janus Kinase (JAK) inhibitors (including tofacitinib, ruxolitinib, baricitinib, ritlecitinib and brepocitinib) for alopecia areata (AA) are yet
Diqin Yan, Diqin Yan, Huaying Fan, Min Chen, Min Chen, Lin Xia, Lin Xia, Simin Wang, Simin Wang, Wenliang Dong, Wenliang Dong, Qian Wang, Suping Niu, Huiying Rao, Liming Chen, Xiaoyan Nie, Yi Fang   +16 more
doaj   +4 more sources

JAK inhibitors in the management of extra-intestinal manifestations in inflammatory bowel disease [PDF]

Therapeutic Advances in Gastroenterology
Extra-intestinal manifestations (EIMs) commonly occur in patients with inflammatory bowel diseases (IBD) and contribute significantly to morbidity and reduced quality of life. Their management remains challenging.
Fotios S. Fousekis, André Jefremow, Konstantinos H. Katsanos, Markus F. Neurath, Raja Atreya   +4 more
doaj   +3 more sources

The safety of JAK-1 inhibitors [PDF]

Rheumatology, 2021
Abstract As efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; monitoring for laboratory ...
Benjamin Clarke, Mark Yates, Maryam Adas, Katie Bechman, James Galloway   +4 more
openaire   +4 more sources

New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors

Immunological Medicine, 2020
The treatment of rheumatoid arthritis (RA) is now entering a new era, the era of Janus kinase (JAK) inhibitors. JAK inhibitors target multiple cytokines including IL-6 and exhibit a beneficial treatment effect in patients with RA and inadequate response ...
Masaru Kato
doaj   +2 more sources

JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis [PDF]

Journal of Immunotherapy and Precision Oncology, 2021
Myelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by uncontrolled blood counts, constitutional symptoms, extramedullary hematopoiesis, and an increased risk of developing acute myeloid leukemia.
Andrew T. Kuykendall, Rami S. Komrokji
doaj   +4 more sources